No, BPC-157 is not a steroid
It is particularly beneficial for those recovering from injuries, experiencing joint issues, or wanting to optimise recovery during intensive training
It involves the development of not only new delivery systems, as well as new therapies
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
My assumption is that, within the next 12-18 months, we will get something from [big] pharma and the FDA stating that a select amount [of peptides] will most likely be deemed Class 1 [from their current Class 2], which will mean that theyre legal to compound [in the U.S
Capsules are pre-measured for consistent dosing and ready to use directly in oral administration research protocols